Vaxcyte, Inc.
Close on Oct 19, 2026
- Market cap
- $9.20B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | – | $-1.97 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | – | $-1.56 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | – | $-1.22 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | – | $-1.04 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | After market close | – | $-0.83 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
Press releases
Announcements Vaxcyte filed with the SEC
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
October 5, 2026 VAX-31 OPUS-1 Pivotal
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Jeff Macdonald, Executive Director, Investor Relations Vaxcyte, Inc. 917-371-0940 [email protected]
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Announces Positive Topline Results from VAX-24 Infant
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the ability of Vaxcyte’s vaccine candidates and platform to achieve the broadest
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
VAX-31 Phase 1/2 Study Topline Results
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent
Other events · EX-99.1 to Form 8-K
VAX-24 Phase 2 Program Results,
Other events · EX-99.2 to Form 8-K
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99 to Form 8-K
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
VAX-24 Phase 1/2 Proof-of-Concept Study
Other events · EX-99.2 to Form 8-K
Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K